Business Wire

Department of Health - Abu Dhabi and ŌURA Partner to Advance Preventive Health in Abu Dhabi

7.5.2026 18:57:00 CEST | Business Wire | Press Release

Share

Department of Health—Abu Dhabi (DoH) and ŌURA, maker of the world’s leading smart ring, Oura Ring, today announced a joint research programme to study how continuous wearable data can advance preventive health. The collaboration marks the beginning of a long-term partnership to advance Abu Dhabi’s prevention-first, data-driven healthcare agenda, and will initially focus on women’s health and cardiometabolic risk.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260507073495/en/

HE Mansoor Al Mansoori (Left) and Tom Hale (Right)

The collaboration builds on Abu Dhabi’s advanced public health infrastructure and longitudinal health data assets, integrating them with ŌURA’s real-time, continuous insights across key health indicators. Together, this creates a strong foundation for understanding health at a population level, enabling the identification of risk factors and supporting a shift from reactive care to more proactive, personalised intervention. The depth of Abu Dhabi’s longitudinal data further strengthens its potential as a platform for population health research, offering deeper insight into how conditions such as obesity, prediabetes, cardiovascular disease, and maternal health risks emerge and evolve.

Initially centred around women’s health, the partnership will explore key research pathways focused on preconception health and perinatal care, supporting the development of more targeted early interventions and improving health trajectories for women, families, and the wider population. The collaboration will also explore other key areas of health, including metabolic and cardiovascular conditions, with a clear ambition to scale successful insights and interventions beyond initial focus areas over time.

The partnership will be supported by robust data governance principles, including data minimization, transparent data processing and secure storage in line with applicable regulations and international best practices. All use of identifiable data will be strictly controlled, with access governed by jointly defined ethical and regulatory standards.

HE Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi, and Tom Hale, CEO of ŌURA met in LA, USA this week to formally launch the partnership and align on the next phase of advancing prevention-led, data-driven healthcare.

HE Al Mansoori commented: “The future of health will be defined by sensing and the ability to understand the body continuously, in real-time, and at population scale. Abu Dhabi has built an intelligent health system designed for this shift. Bringing real-world wearable data into the clinical setting, underpinned by strong data governance frameworks that ensure privacy and responsible use of health data.

“Advancing women's health and fertility is a key priority for Abu Dhabi, and together with ŌURA we are starting where continuous insights have the greatest power to detect risk earlier and create more personalised care across the life course - for mothers, babies, and families. This partnership brings together one of the world’s most advanced population health datasets with continuous wearable insights at scale, creating a unique opportunity to redefine how prevention is delivered in real-world settings.”

Tom Hale said: “Abu Dhabi is setting a powerful example for how nations can embed prevention and innovation into the future of healthcare. Partnering with the Department of Health – Abu Dhabi will allow us to build a meaningful preventative health model that is grounded in data, scientific rigor and privacy. It’s one of many upcoming initiatives we’re committed to across the region, and an important step in our long-term partnership with Abu Dhabi.

We’re starting with women’s health, because the health of women is the health of families, and the health of families is the health of the nation. But this partnership is just the beginning — our ambition is to develop a model here that can inform preventive care globally.”

The agreement marks a significant milestone in ŌURA’s continued expansion across the UAE and wider Gulf region, as the company deepens its presence through strategic partnerships, locally relevant research, and innovation aligned with the UAE’s emergence as a world leader in prevention-led healthcare and long-term wellbeing.

The next phase of the partnership will focus on pilot design, ethics approvals, and local evidence generation, creating a clear pathway toward broader integration within Abu Dhabi’s health system.

About the Department of Health –Abu Dhabi (DoH):

The Department of Health – Abu Dhabi is the regulative body of the healthcare sector in the Emirate of Abu Dhabi. Committed to ensuring excellence in healthcare, DoH monitors the health status of the population while shaping the regulatory framework for the health system. This includes inspecting against regulations, enforcing standards and encouraging the adoption of world-class best practices and performance targets by all healthcare providers in the Emirate. Abu Dhabi remains dedicated to shaping the future of healthcare by establishing an intelligent and sustainable ecosystem that prioritises health, longevity and quality of life for all community members. Leveraging state-of-the-art infrastructure and cutting-edge capabilities, DoH continues to develop and implement initiatives and programmes in line with its strategic focus areas, Healthy Population, Best-in-Class Care and Resilience and Innovation. These efforts reflect DoH’s unwavering commitment to predicting, preventing and personalising healthcare for every individual.

For further information on DOH, visit https://www.doh.gov.ae/ and follow on X, Instagram, Facebook, LinkedIn and YouTube.

About ŌURA:

ŌURA delivers personalized health data, insights, and daily guidance with Oura Ring, the leading smart ring that helps you live healthier, longer. Guided by a mission to shift healthcare from sick care to prevention, ŌURA supports millions of members worldwide across sleep, activity, stress, readiness, women’s health, and heart health. Scientifically validated against medical gold standards, the lightweight Oura Ring tracks 50+ health metrics continuously, empowering both individuals and thousands of research teams, healthcare providers, and organizations. With 1,000 ecosystem partners across wellness and medicine, ŌURA is advancing the future of preventative health.

Founded in Finland in 2013, ŌURA has E.U. headquarters in Oulu and U.S. headquarters in San Francisco. ŌURA was last valued at approximately $11B—making it the world’s most valuable standalone wearable company. Learn more at ouraring.com or connect with ŌURA on Instagram, LinkedIn, and TikTok.

Oura Ring is not a medical device and is not intended to diagnose, treat, cure, monitor, or prevent medical conditions or illnesses.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260507073495/en/

Contacts

ŌURA
For press enquiries contact:
oura@currentglobal.com

Department of Health – Abu Dhabi
For media inquiries, please contact:
Mariam Al Marzooqi,
msalmarzooqi@doh.gov.ae
+971 50 536 6660

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

VerSprite Launches Fork and Knife: AI-Driven Threat Modeling and Adversarial Testing Built for the Speed of Modern Software26.6.2026 23:28:00 CEST | Press Release

VerSprite, a global leader in risk-based threat modeling and the firm behind the PASTA (Process for Attack Simulation and Threat Analysis) methodology, today announced the general availability of Fork (www.forktm.com), a continuous application threat modeling platform, alongside Knife, an AI-led, human-on-the-loop adversarial testing platform for web applications and web API endpoints. Together, the two products operationalize a new model for product security—one where applications are securely designed, continuously modeled, and actively tested as part of the build process itself. The launch addresses a problem every security leader knows but few tools have solved: threat modeling is essential, never more so than in an AI-driven era, yet it has remained slow, manual, and anchored to frameworks designed for a different threat landscape. The problem: threat modeling matters more than ever—and most tools are stuck in 2005 For two decades, application threat modeling has leaned heavily on

Venture Global Announces Closing of $1.5 Billion Senior Secured Vessel Financing Facility26.6.2026 22:30:00 CEST | Press Release

Venture Global, Inc. (NYSE: VG) announced today that its wholly-owned subsidiary, Venture Global Shipping Holdings, LLC (“VGSH”), has entered into a Credit and Guaranty Agreement providing for a senior secured term loan facility (the “Facility”) in an aggregate principal amount of up to $1,500,000,000. The Facility will mature on June 26, 2032. Deutsche Bank and ING acted as coordinating lead arrangers for the Facility. ING also serves as facility agent and security trustee. VGSH intends to use the net proceeds from the Facility for general corporate purposes, including to reimburse Venture Global LNG, Inc. for payments previously made by it or its affiliates in connection with the acquisition of nine LNG carriers, funding certain reserve accounts, and paying transaction fees and expenses. About Venture Global Venture Global is an American producer and exporter of low-cost U.S. liquefied natural gas (“LNG”) with over 100 MTPA of capacity in production, construction, or development. Ven

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press Release

Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solution – uses digital twin technology to identify vulnerable customers and recommend explainable next-best actions for fro

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press Release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press Release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye